SLC5A2 and myocardial infarction: It includes energy-depleting acute myocardial ischemia, early reperfusion injury that develops in the first few minutes or hours of reperfusion, and the remodeling phase that occurs in the early days or weeks following myocardial infarction, which results in irreversible necrotic damage to the area of concern [2]. Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) improves cardiovascular outcomes in high-risk patients with type 2 diabetes, those with chronic kidney disease, and those with heart failure with a reduced or preserved left ventricular ejection fraction [3].